Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon Oct 12, 2015 4:32pm

159 Views

Post# 24185263

RE:Eli Lilly Drops Its CETP Inhibitor, Evacetrapib

Thanks for sharing that story JD. That is crazy, since on July 27, 2015 the ACCELERATE study data monitoring committee just recommended continuing the trial! I guess they changed their minds less than 3 months later.

Just one small correction. In addition to Merck's anacetrapib that is still in Phase III, there is another "promising" CETP inhibitor from Dezima called TA-8995 that is in Phase II right now. Dezima was just recently purchased by Amgen (see this story for reference).

BDAZ

Bullboard Posts

Mullen Group's Robust Case for Value, Part 1: Less-than-Truckload